Aduro Biotech presents BION-1301 data at ASH

Aduro Biotech announced preclinical data in two abstracts for its first-in-class anti-APRIL antibody BION-1301 supporting its potential use as a treatment for multiple myeloma, or MM, at the American Society of Hematology, or ASH. Data from the studies demonstrated that therapies blocking a proliferation inducing ligand, or APRIL, from binding to B cell maturation antigen, or BCMA, and transmembrane activator and cyclophilin ligand interactor, or TACI, may simultaneously target MM cells and APRIL-induced immunosuppression. Moreover, studies showed patient serum levels of APRIL were elevated at all stages of MM investigated, suggesting a role for APRIL in early development and pathogenesis. In addition, APRIL was found to induce production of key chemokines with osteolytic capacity. Blocking APRIL could modulate the tumor microenvironment more broadly, illustrating the potential of BION-1301 as a therapeutic agent for MM, particularly in combination therapies. Aduro is currently conducting a Phase 1/2 multi-center, open-label study designed to evaluate the safety and activity of BION-1301 in patients with relapsed or refractory MM whose disease has progressed after at least 3 prior systemic therapies, including immunomodulatory drugs, proteasome inhibitors, chemotherapies, or monoclonal antibodies.
https://thefly.com/landingPageNews.php?id=2831145